Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 2, 2015, Pages 430-441

  Juengel, Eva ^a   Kim, Dana ^a   Makarević, Jasmina ^a   Reiter, Michael ^a   Tsaur, Igor ^a   Bartsch, Georg ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

RAD001; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib

Indexed keywords

RAPTORES;

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EVEROLIMUS; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB;

ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; HUMAN; KIDNEY NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; EVEROLIMUS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; SIROLIMUS;

EID: 84921817215     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12471     Document Type: Article

References (36)

1. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011; 16: 14-22.
2. Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011; 47: 1287-98.
3. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009; 104: 1585-9.
4. Park K, Lee JL, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol. 2012; 29: 3291-7.
5. Iacovelli R, Palazzo A, Trenta P, et al. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. Am J Clin Oncol. 2013; in press.
6. Juengel E, Dauselt A, Makarević J, et al. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett. 2012; 324: 83-90.
7. Juengel E, Engler J, Natsheh I, et al. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer. 2009; 9: 161.
8. Tsaur I, Makarević J, Juengel E, et al. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells. Br J Cancer. 2012; 107: 847-55.
9. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010; 58: 398-406.
10. Teng CL, Yu CT, Hwang WL, et al. Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells. Ann Hematol. 2013; 92: 301-13.
11. Kruck S, Merseburger AS, Hennenlotter J, et al. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int. 2012; 109: 1565-70.
12. Pertia A, Nikoleishvili D, Trsintsadze O, et al. Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol. 2007; 39: 381-7.
13. Hosono T, Tanaka T, Tanji K, et al. NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. Br J Cancer. 2010; 102: 873-82.
14. Zhang T, Zheng J, Jiang N, et al. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma. Cancer Lett. 2009; 283: 59-67.
15. Macaluso M, Montanari M, Cinti C, et al. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005; 32: 452-7.
16. Lin P, Sun X, Feng T, et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem. 2012; 359: 235-43.
17. Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle. 2012; 11: 4305-9.
18. Sakai I, Miyake H, Fujisawa M. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int. 2013; in press.
19. Tsaur I, Makarević J, Hudak L, et al. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett. 2011; 313: 84-90.
20. Kim EH, Kim HS, Kim SU, et al. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene. 2005; 24: 6877-89.
21. Hassan KA, Ang KK, El-Naggar AK, et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 2002; 62: 6414-7.
22. Serova M, de Gramont A, Tijeras-Raballand A, et al. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol. 2013; 71: 1297-307.
23. Miyake M, Anai S, Fujimoto K, et al. 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett. 2012; 3: 1195-202.
24. Menke J, Kriegsmann J, Schimanski CC, et al. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res. 2012; 72: 187-200.
25. Larkin J, Esser N, Calvo E, et al. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer Res. 2012; 32: 2399-406.
26. Shiota M, Eto M, Yokomizo A, et al. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int J Oncol. 2010; 36: 1521-31.
27. Porta C, Procopio G, Cartenì G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011; 108: E250-7.
28. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009; 182: 29-34.
29. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009; 36: S3-17.
30. Zeng Z, dos Sarbassov D, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007; 109: 3509-12.
31. Mancini M, Petta S, Martinelli G, et al. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem. 2010; 109: 320-8.
32. Rosa R, Damiano V, Nappi L, et al. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer. 2013; 109: 686-93.
33. Chen CC, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2012; 10: 256-61.
34. Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011; 12: 1491-7.
35. Shablak A, Gilham DE, Hawkins RE, et al. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin Pharmacother. 2014; 15: 1489-99.
36. Kususda Y, Miyake H, Gleave ME, et al. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer. 2012; 106: 1945-52.